Drug-maker Valeant on course to debt repayment target: CEO

LAVAL, Quebec (Reuters) - Valeant Pharmaceuticals International Inc , weighed down by debt from years of acquisitions, is on pace to meeting its target of repaying $5 billion in debt between August, 2016 and February, 2018, Chief Executive Joe Papa told shareholders on Tuesday.

Drug-maker Valeant on course to debt repayment target: CEO
Read More


Bagikan Berita Ini